190 related articles for article (PubMed ID: 34992612)
1. Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome.
Yin Z; Tian X; Zou R; He X; Chen K; Zhu C
Front Immunol; 2021; 12():813261. PubMed ID: 34992612
[TBL] [Abstract][Full Text] [Related]
2. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review.
Yang X; Xi R; Bai J; Pan Y
Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Activating
Lu M; Gu W; Sheng Y; Wang J; Xu X
Front Immunol; 2021; 12():670312. PubMed ID: 33995405
[TBL] [Abstract][Full Text] [Related]
4. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
[TBL] [Abstract][Full Text] [Related]
5. A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting With Hemophagocytosis Complicated With Hodgkin Lymphoma.
Cansever M; Zietara N; Chiang SCC; Ozcan A; Yilmaz E; Karakukcu M; Rohlfs M; Somekh I; Canoz O; Abdulrezzak U; Bryceson Y; Klein C; Unal E; Patiroglu T
J Pediatr Hematol Oncol; 2020 Mar; 42(2):156-159. PubMed ID: 31033788
[TBL] [Abstract][Full Text] [Related]
6. The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-δ (PI3Kδ) Syndrome (APDS).
Fekrvand S; Delavari S; Chavoshzadeh Z; Sherkat R; Mahdaviani SA; Sadeghi Shabestari M; Azizi G; Arzanian MT; Shahin Shamsian B; Eskandarzadeh S; Eslami N; Rae W; Condino-Neto A; Mohammadi J; Abolhassani H; Yazdani R; Aghamohammadi A
Immunol Invest; 2022 Apr; 51(3):644-659. PubMed ID: 33401995
[TBL] [Abstract][Full Text] [Related]
7. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI; Chandra A; Bacon CM; Babar J; Curtis J; Screaton N; Goodlad JR; Farmer G; Steele CL; Leahy TR; Doffinger R; Baxendale H; Bernatoniene J; Edgar JD; Longhurst HJ; Ehl S; Speckmann C; Grimbacher B; Sediva A; Milota T; Faust SN; Williams AP; Hayman G; Kucuk ZY; Hague R; French P; Brooker R; Forsyth P; Herriot R; Cancrini C; Palma P; Ariganello P; Conlon N; Feighery C; Gavin PJ; Jones A; Imai K; Ibrahim MA; Markelj G; Abinun M; Rieux-Laucat F; Latour S; Pellier I; Fischer A; Touzot F; Casanova JL; Durandy A; Burns SO; Savic S; Kumararatne DS; Moshous D; Kracker S; Vanhaesebroeck B; Okkenhaug K; Picard C; Nejentsev S; Condliffe AM; Cant AJ
J Allergy Clin Immunol; 2017 Feb; 139(2):597-606.e4. PubMed ID: 27555459
[TBL] [Abstract][Full Text] [Related]
8. Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype.
Zhao P; Huang J; Fu H; Xu J; Li T; Zhang X; Meng Q; Zhang L; Tan L; Zhang W; Chen H; Lu X; Ding Y; He X
Pediatr Rheumatol Online J; 2024 Jan; 22(1):24. PubMed ID: 38287413
[TBL] [Abstract][Full Text] [Related]
9. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
Condliffe AM; Chandra A
Front Immunol; 2018; 9():338. PubMed ID: 29556229
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and immunological analysis of patients with activated phosphoinositide 3-kinase δ syndrome resulting from PIK3CD mutation].
Tang WJ; Wang W; Luo Y; Wang YP; Li L; An YF; Gou LJ; Ma MS; He TY; Yang J; Zhao XD; Song HM
Zhonghua Er Ke Za Zhi; 2017 Jan; 55(1):19-24. PubMed ID: 28072954
[No Abstract] [Full Text] [Related]
11. Immunodeficiency due to a novel variant in PIK3CD: a case report.
Shashaani N; Chavoshzadeh Z; Ghasemi L; Ghotbabadi SH; Shiari S; Sharafian S; Shiari R
Pediatr Rheumatol Online J; 2023 Jul; 21(1):71. PubMed ID: 37475052
[TBL] [Abstract][Full Text] [Related]
12. Activated Phosphoinositide 3-Kinase δ Syndrome: a Large Pediatric Cohort from a Single Center in China.
Qiu L; Wang Y; Tang W; Yang Q; Zeng T; Chen J; Chen X; Zhang L; Zhou L; Zhang Z; An Y; Tang X; Zhao X
J Clin Immunol; 2022 May; 42(4):837-850. PubMed ID: 35296988
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of mortality and survival rates for APDS.
Hanson J; Bonnen PE
Clin Exp Med; 2024 Jan; 24(1):17. PubMed ID: 38280023
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome: Case Report and Review.
Schworer SA; Francis OL; Johnson SM; Smith BD; Gold SH; Smitherman AB; Wu EY
J Pediatr Hematol Oncol; 2021 Nov; 43(8):281-287. PubMed ID: 34054047
[TBL] [Abstract][Full Text] [Related]
15. E1021K Homozygous Mutation in PIK3CD Leads to Activated PI3K-Delta Syndrome 1.
Wang Y; Chen X; Yang Q; Tang W; Jia Y; Zhou L; An Y; Zhang Z; Tang X; Zhao X
J Clin Immunol; 2020 Feb; 40(2):378-387. PubMed ID: 31953711
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J
Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
[TBL] [Abstract][Full Text] [Related]
17. Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.
Wang Y; Wang W; Liu L; Hou J; Ying W; Hui X; Zhou Q; Liu D; Yao H; Sun J; Wang X
J Clin Immunol; 2018 Nov; 38(8):854-863. PubMed ID: 30499059
[TBL] [Abstract][Full Text] [Related]
18. Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma.
Durandy A; Kracker S
Blood; 2020 Feb; 135(9):638-643. PubMed ID: 31942637
[TBL] [Abstract][Full Text] [Related]
19. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME; Abolhassani H; Aghamohammadi A; Aiuti A; Aleinikova O; Bangs C; Baris S; Barzaghi F; Baxendale H; Buckland M; Burns SO; Cancrini C; Cant A; Cathébras P; Cavazzana M; Chandra A; Conti F; Coulter T; Devlin LA; Edgar JDM; Faust S; Fischer A; Garcia-Prat M; Hammarström L; Heeg M; Jolles S; Karakoc-Aydiner E; Kindle G; Kiykim A; Kumararatne D; Grimbacher B; Longhurst H; Mahlaoui N; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neven B; Nieters A; Olbrich P; Ozen A; Pachlopnik Schmid J; Picard C; Prader S; Rae W; Reichenbach J; Rusch S; Savic S; Scarselli A; Scheible R; Sediva A; Sharapova SO; Shcherbina A; Slatter M; Soler-Palacin P; Stanislas A; Suarez F; Tucci F; Uhlmann A; van Montfrans J; Warnatz K; Williams AP; Wood P; Kracker S; Condliffe AM; Ehl S
Front Immunol; 2018; 9():543. PubMed ID: 29599784
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and genetic analysis for activated PI3K-δ syndrome by PIK3CD gene mutation].
Liu H; Tang XL; Liu JR; Li HM; Zhao SY
Zhonghua Er Ke Za Zhi; 2016 Sep; 54(9):698-702. PubMed ID: 27596086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
